论文部分内容阅读
目的:应用心率变异性的方法观察心可舒片对早搏的治疗效果及其影响。方法:将96例频发早搏患者随机分成治疗组(51例)和对照组(45例)。对照组给予倍他乐克缓释片口服,47.5mg/次,1次/日,治疗组在口服倍他乐克缓释片基础上加用心可舒片4片/次,3次/日。在服药前及服药后1个月各行1次动态心电图及普通心电图检查,并进行临床观察。结果:治疗组在消除早搏,改善临床症状方面较对照组明显有效(P<0.05),治疗组较对照组心率变异性改善有明显差异(P<0.05)。结论:心可舒片与倍他乐克合用可有效增加其治疗早搏的作用,同时改善心率变异性和改善倍他乐克引起的窦性心动过缓副作用,有较好的临床疗效。
OBJECTIVE: To observe the therapeutic effects and its effects of Xinkeshu tablets on premature beats by using the method of heart rate variability. Methods: 96 patients with premature beats were randomly divided into treatment group (51 cases) and control group (45 cases). The control group was given Betaloc sustained-release tablets orally, 47.5mg / time, 1 time / day, the treatment group in the oral release of Betaloc on the basis of plus XK tablets 4 tablets / time, 3 times / day. Before taking the medication and 1 month after taking a line of dynamic Holter and ordinary ECG, and clinical observation. Results: The treatment group was significantly better than the control group in eliminating premature beat and improving the clinical symptoms (P <0.05), and the improvement of heart rate variability in the treatment group was significantly different from that in the control group (P <0.05). Conclusion: The combination of Xinkeshu Tablet and Betaloc can effectively increase its effect on treating premature beats, improve the heart rate variability and improve the side effects of valoclazac caused by sinus bradycardia, which has a good clinical effect.